Literature DB >> 25571897

Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer.

Xiao-Jin Wu1, Xiao-Dong Li2, Hanze Zhang3, Xiaofei Zhang4, Zhong-Hua Ning5, Yong-Mei Yin6, Ye Tian7.   

Abstract

OBJECTIVES: To evaluate levels of CD44 standard variant (CD44s), CD44 variant exon 3 (CD44v3) and CD44 variant exon 6 (CD44v6) protein in breast cancer tissue, and investigate their relationships with clinicopathological characteristics of the disease.
METHODS: Immunohistochemistry for CD44s, CD44v3 and CD44v6 was retrospectively performed on formalin-fixed paraffin wax-embedded breast cancer tissue samples.
RESULTS: Tumour tissue samples from 60 patients with breast cancer were included. There was a significant relationship between CD44s positivity and tumour diameter and lymph node involvement. CD44v6 positivity was significantly associated with tumour-node-metastasis (TNM) stage and lymph node involvement. There were significant negative correlations between CD44s immunopositivity, tumour diameter and TNM stage, and significant positive correlations between CD44v6 immunopositivity, tumour diameter and TNM stage.
CONCLUSIONS: CD44s and CD44v6 appear to play opposing roles in the development of breast cancer, but their precise functions and mechanisms of action remain unclear.
© The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Breast cancer; CD44; adhesion molecule; clinical significance; immunohistochemistry

Mesh:

Substances:

Year:  2015        PMID: 25571897     DOI: 10.1177/0300060514559793

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

Review 1.  The role of CD44 in epithelial-mesenchymal transition and cancer development.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Hua Wu; Qian Liu; Richard G Pestell; Kongming Wu
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

2.  Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.

Authors:  Anja C Mortensen; Diana Spiegelberg; Anna-Karin Haylock; Hans Lundqvist; Marika Nestor
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

3.  CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.

Authors:  Ruifang Gao; Dan Li; Jing Xun; Wei Zhou; Jun Li; Juan Wang; Chen Liu; Xiru Li; Wenzhi Shen; Huan Qiao; Dwayne G Stupack; Na Luo
Journal:  Theranostics       Date:  2018-11-29       Impact factor: 11.556

4.  Prognostic value of CD44v6 expression in breast cancer: a meta-analysis.

Authors:  Guang-Lei Qiao; Li-Na Song; Zhou-Feng Deng; Ying Chen; Li-Jun Ma
Journal:  Onco Targets Ther       Date:  2018-09-04       Impact factor: 4.147

5.  Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.

Authors:  Tony Navas; Thomas D Pfister; Simona Colantonio; Amina Aziz; Lynda Dieckman; Richard G Saul; Jan Kaczmarczyk; Suzanne Borgel; Sergio Y Alcoser; Melinda G Hollingshead; Young H Lee; Donald P Bottaro; Tara Hiltke; Gordon Whiteley; Naoko Takebe; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

6.  Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing.

Authors:  Shaocheng Wu; Hongjiu Zhang; Shamileh Fouladdel; Hongyang Li; Evan Keller; Max S Wicha; Gilbert S Omenn; Ebrahim Azizi; Yuanfang Guan
Journal:  Comput Struct Biotechnol J       Date:  2020-03-19       Impact factor: 7.271

7.  Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.

Authors:  Anja C L Mortensen; Eric Morin; Christopher J Brown; David P Lane; Marika Nestor
Journal:  EJNMMI Res       Date:  2020-04-16       Impact factor: 3.138

Review 8.  Significance of alternative splicing in cancer cells.

Authors:  Fei Qi; Yong Li; Xue Yang; Yan-Ping Wu; Lian-Jun Lin; Xin-Min Liu
Journal:  Chin Med J (Engl)       Date:  2020-01-20       Impact factor: 2.628

9.  Direct interaction of TrkA/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells.

Authors:  Sarah Trouvilliez; Julien Cicero; Romain Lévêque; Léo Aubert; Cyril Corbet; Alexandre Van Outryve; Karolin Streule; Pierre-Olivier Angrand; Pamela Völkel; Romain Magnez; Guillaume Brysbaert; Caroline Mysiorek; Fabien Gosselet; Roland Bourette; Eric Adriaenssens; Xavier Thuru; Chann Lagadec; Jérôme de Ruyck; Véronique Orian-Rousseau; Xuefen Le Bourhis; Robert-Alain Toillon
Journal:  J Exp Clin Cancer Res       Date:  2022-03-28

10.  Prognostic value of CD44v9 expression in human cancers: A systematic review and meta-analysis.

Authors:  Li Zeng; Yitian Chen; Ligang Chen; Chengwei Tang
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.